STW:PA:PA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 205.85

Change

+2.85 (+1.40)%

Market Cap

USD 0.66B

Volume

1.65K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.25 (-0.55%)

USD 56.03B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+0.30 (+0.06%)

USD 13.60B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+1.02 (+0.29%)

USD 11.29B
WRD:PA HSBC MSCI World UCITS ETF

+0.09 (+0.27%)

USD 11.04B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

+1.11 (+0.45%)

USD 10.45B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

+0.30 (+0.07%)

USD 8.68B
WLD:PA Lyxor UCITS MSCI World D-EUR

+0.97 (+0.31%)

USD 7.49B
HHH:PA HSBC S&P 500 UCITS ETF

+0.01 (+0.02%)

USD 7.22B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

+0.03 (+0.54%)

USD 6.16B
SPY4:PA SSgA SPDR S&P 400 US Mid Cap

-0.10 (-0.13%)

USD 5.38B

ETFs Containing STW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.74% 50% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.74% 49% F 48% F
Trailing 12 Months  
Capital Gain -6.05% 10% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.05% 10% F 34% F
Trailing 5 Years  
Capital Gain 27.81% 32% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.81% 30% F 45% F
Average Annual (5 Year Horizon)  
Capital Gain 9.16% 57% F 64% D
Dividend Return 9.16% 54% F 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.19% 77% C+ 86% B+
Risk Adjusted Return 111.91% 93% A 95% A
Market Capitalization 0.66B 70% C- 73% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike